M Zaffaroni
Overview
Explore the profile of M Zaffaroni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
706
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Dondi E, Sogni S, Zaffaroni M, Bona G
Panminerva Med
. 2008 Apr;
50(1):81-2.
PMID: 18427391
No abstract available.
22.
Ghezzi A, Amato M, Capobianco M, Gallo P, Marrosu M, Martinelli V, et al.
Neurol Sci
. 2007 Jul;
28(3):127-32.
PMID: 17603763
The objective was to evaluate the safety, tolerability and effectiveness of intramuscular (IM) interferon beta-1a (IFNbeta-1a; Avonex, Biogen) 30 mg once a week in patients with onset of symptoms of...
23.
Sarchielli P, Zaffaroni M, Floridi A, Greco L, Candeliere A, Mattioni A, et al.
Mult Scler
. 2007 Apr;
13(3):313-31.
PMID: 17439900
Sixty, relapsing remitting (RR) multiple sclerosis (MS) patients, who underwent treatment with glatiramer acetate (GA), interferon (IFN)-beta 1a, and immunoglobulins (Igs) (20 per treatment group), were assessed for levels of...
24.
Frapolli R, Marangon E, Zaffaroni M, Colombo T, Falcioni C, Bagnati R, et al.
Drug Metab Dispos
. 2006 Sep;
34(12):2028-35.
PMID: 16963486
IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III) is a new taxane, derived from 7,8-C-seco-10-deacetylbaccatin, selected for its ability to inhibit angiogenesis, mainly by acting on endothelial cell motility, and for its selective activity...
25.
Guala A, Guarino R, Campra D, Zaffaroni M, Pastore G, Lingua S, et al.
Pediatr Med Chir
. 2006 Aug;
27(6):29-33.
PMID: 16922010
Objectives: To record the prevalence of the sleeping position of sucklings living in the ASL 11-Regione Piemonte; to make an information campaign about the utility of sleeping in the supine...
26.
Zaffaroni M, Ghezzi A, Comi G
Neurol Sci
. 2006 May;
27 Suppl 1:S13-7.
PMID: 16708175
Immunosuppressive drugs have been used out of label in multiple sclerosis (MS) for over 30 years and around 10% of patients are actually under immunosuppressive treatment. The rationale for immunosuppression...
27.
Bellone S, Baldelli R, Radetti G, Rapa A, Vivenza D, Petri A, et al.
J Clin Endocrinol Metab
. 2006 Mar;
91(5):1929-33.
PMID: 16522697
Context: Ghrelin, a natural GH secretagogue, is mainly characterized by nonendocrine activities such as orexigenic effect and modulation of the endocrine and metabolic response to variations in energy balance. Ghrelin...
28.
Zaffaroni M
Neurol Sci
. 2006 Jan;
26 Suppl 4:S187-92.
PMID: 16388356
Not all patients with multiple sclerosis (MS) respond equally to available disease modifying agents (DMA). Rational and reliable criteria are needed to identify responders and non responders in order to...
29.
Ghezzi A, Amato M, Capobianco M, Gallo P, Marrosu G, Martinelli V, et al.
Mult Scler
. 2005 Jul;
11(4):420-4.
PMID: 16042224
Objective: Immunomodulatory drugs (IDs) (interferon beta (IFNgamma) and glatiramer acetate (GA)) reduce relapse rate and disease progression in relapsing remitting multiple sclerosis (RRMS) but extensive data are not available on...
30.
Cadario F, Vercellotti A, Trada M, Zaffaroni M, Rapa A, Iafusco D, et al.
J Endocrinol Invest
. 2005 Mar;
27(10):913-8.
PMID: 15762037
The aim of this study was to evaluate the age of immigrants' children at diagnosis of Type 1 diabetes (T1DM) according to their country of birth. Immigration from developing countries...